Inactive Instrument

Motif Bio plc

Equities

MTFB

GB00BVVT4H71

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Motif Bio plc

MOTF BIO : BiVictriX Debuts on London's AIM Segment After $10 Million IPO	21-08-11	MT
Motif Bio plc Announces Board Appointments	21-06-14	CI
BiVictriX Therapeutics Ltd. cancelled the acquisition of Motif Bio plc in a reverse merger transaction.	21-06-13	CI
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-10	CI
Motif Bio plc Announces Board Changes	21-05-10	CI
Orange Avenue Technologies LLC entered into a Stock Purchase Agreement to acquire Motif BioSciences, Inc. from Motif Bio plc	21-02-25	CI
Motif Bio : Signs Reverse Takeover of Antibody-Drug Conjugate Company	21-01-27	MT
BiVictriX Therapeutics Ltd. entered into a sale and purchase agreement to acquire Motif Bio plc for £5.5 million in a reverse merger transaction.	21-01-26	CI
Motif Bio plc Reports Earnings Results for the Half Year Ended June 30, 2020	20-10-12	CI
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2019	20-09-01	CI
Motif Bio plc Announces Delay in Publication of Final Results for the Year Ended 31 December 2019	20-06-22	CI
Motif Bio Appoints Adviser for Reverse Takeover Candidate	20-06-01	CI
Motif Seeks Reverse Takeover Candidate	20-05-05	CI
Motif Bio plc Announces Management Changes	20-05-04	CI
Motif Bio plc and Motif BioSciences Inc. Enter into Loan Amendment and Release Agreement with Hercules Capital In	20-01-29	CI
Motif Bio plc(NasdaqCM:MTFB) dropped from NASDAQ Composite Index	19-12-16	CI
Motif Bio plc Announces Directorate Changes	19-11-18	CI
Motif Bio plc Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-30	CI
Motif Bio plc and Hercules Capital Amend Loan and Security Agreement	19-09-02	CI
Motif Bio plc to Evaluate Iclaprim Activity Against Listeria	19-08-19	CI
Motif Bio plc Amends Loan and Security Agreement with Hercules Capital, Inc	19-08-01	CI
Motif Bio Confirms Meeting Date with U.S. FDA Regarding Iclaprim	19-07-26	CI
Motif Bio plc Submits Meeting Request and Package to the U.S. Food & Drug Administration Related for iclaprim	19-07-15	CI
Motif Bio plc Presents New Iclaprim Data at ASM Microbe 2019	19-06-24	CI
Transcript : Motif Bio plc - Special Call	19-06-06

Chart Motif Bio plc

Duration

Period

More charts

Company Profile

Motif Bio plc is a United Kingdom-based shell company. The Company is not engaged in any operation.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs